- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Effects of Pegcetacoplan to Slow Progression of GA Increase Over Time: Dr Eleonora Lad
For patients with geographic atrophy (GA) taking pegcetacoplan, the drug’s effect to slow disease progression increases over time as patients take the drug, said Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
For patients with geographic atrophy (GA) taking pegcetacoplan, the drug’s effect to slow disease progression increases over time as patients take the drug, said Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
Transcript
How do the 2-year outcomes of the DERBY and OAKS trials of pegcetacoplan in geographic atrophy update previous findings?
The data presented today reinforces the potential of this drug in geographic atrophy. So, we're continuing to see a reduction in GA lesion growth, and importantly, these effects increase over time. The data suggest that pegcetacoplan is preserving more and more of the retinal cells responsible for vision over time, so we are preventing vision loss. These data also show that pegcetacoplan is continuing to demonstrate a favorable safety profile.
Patients receiving pegcetacoplan were either receiving the shot once a month or every other month. What was the difference in outcomes?
So, in terms of efficacy, we saw a reduction in GA lesion growth in patients who receive both monthly and every other month treatment. The effect was stronger with monthly treatments, so a slightly stronger effect in patients who received the monthly injections. However, the 2 options give the patient a lot of flexibility in terms of visits to clinic and interventions. In regards to safety, there were fewer new-onset exudations in the every other month group. So, this will be an important part of the conversation we as clinicians will have to have with our patients that we're considering treatment for.
Last thoughts?
Perhaps it's important to state again: the longitudinal data with pegcetacoplan show that it slows disease progression with increased effects over time. So, basically, what this means for affected patients is that the drug works better and better the longer they take the drug. The fact that drug works better over time means it has a positive effect, and the patients should have the hope that they're preventing retinal degeneration more as they take the drug over longer time intervals.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
